Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.60-9.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TNXP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
[/TABLE] Payer Access and Coverage [TABLE] ● | The Company is prioritizing ongoing engagement with commercial payers, managed Medicare, and Medicaid to increase access: [/TABLE] [TABLE] ○ | Tonix ann…
Stated in 2 of 2 supplied quarters. Management reported: “|| ○ | Currently, total coverage for TONMYA across commercial, managed Medicare, and Medicaid channels represents approximately 136 million covered lives (~43% of the approximately 314 million covered lives in the U.S.).” “Total commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of approximately 314 million total U.S. lives).”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“[/TABLE] Payer Access and Coverage [TABLE] ● | The Company is prioritizing ongoing engagement with commercial payers, managed Medicare, and Medicaid to increase access: [/TABLE] [TABLE] ○ | Tonix ann…”
“We will continue engagement with commercial and government payers to expand patient access.”
Approximately 50 new sales force representatives have been fully activated in the field, bringing the total sales force to 150 representatives.
Stated in 1 of 2 supplied quarters. Management reported: “The Company expects to deploy 50 new sales representatives in the field by September 2026, bringing the full sales force to approximately 150 people.” “Approximately 50 new sales force representatives have been fully activated in the field, bringing the total sales force to 150 representatives.”
“The Company expects to deploy 50 new sales representatives in the field by September 2026, bringing the full sales force to approximately 150 people.”
We enrolled the first patient in HORIZON, our potentially pivotal Phase 2 study of TNX-102 SL in MDD.
Stated in 2 of 2 supplied quarters. Management reported: “Approximately 360 patients are expected to enroll at approximately 30 U.S. sites, with the primary endpoint of change from baseline in MADRS (Montgomery-Asberg Depression Rating Scale) total score at Week 6.” “We enrolled the first patient in HORIZON, our potentially pivotal Phase 2 study of TNX-102 SL in MDD.”
“We enrolled the first patient in HORIZON, our potentially pivotal Phase 2 study of TNX-102 SL in MDD.”
“Tonix plans to initiate enrollment in mid-2026.”
The adaptive Phase 2 field study is expected to start in the first quarter of 2027 pending final FDA review and agreement on the study protocol.
Stated in 2 of 2 supplied quarters. Management reported: “The adaptive Phase 2 field study is expected to start in the first quarter of 2027 pending final FDA review and agreement on the study protocol.” “Infectious Disease Pipeline TNX-4800 (anti-OspA mAb): Phase 2-ready long-acting human monoclonal antibody in development for the seasonal prevention of Lyme disease in the U.S., which has no FDA-approved vaccines or prophylactics • In March 2026, Tonix presented Phase 1 data at the World Vaccine Congress Washington 2026 and announced plans to initiate an adaptive Phase 2 field study in the first half of 2027, pending FDA agreement.”
“The adaptive Phase 2 field study is expected to start in the first quarter of 2027 pending final FDA review and agreement on the study protocol.”
“Infectious Disease Pipeline TNX-4800 (anti-OspA mAb): Phase 2-ready long-acting human monoclonal antibody in development for the seasonal prevention of Lyme disease in the U.S., which has no FDA-appr…”
Progress the Phase 2 HORIZON study of TNX-102 SL as a first-line monotherapy for major depressive disorder.
Over the trailing year it converted 1.04x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
51 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.